Skip to main content

Table 3 Correlations between subtype and clinicopathological parameters in 71 mucinous breast carcinomas

From: Clinical significance of the sub-classification of 71 cases mucinous breast carcinoma

Parameters MBC (n=71) p value PMBC (n=48) p value
  MMBC (n=23) PMBC (n=48)   PMBC-A (n=32) PMBC-B (n=16)  
Age at operation 14 (60.9%) 24 (50.0%) 0.390 14 (43.8%) 10 (62.5%) 0.220
  ≤64 9 (39.1%) 24 (50.0%)   18 (56.2%) 6 (37.5%)  
  >64       
Pathological stage 9 (39.1%) 14 (29.2%) 0.401 8 (25.0%) 6 (37.5%) 0.369
  I 14 (60.9%) 34 (70.8%)   24 (75.0%) 10 (62.5%)  
  II and III       
pTumor size 11 (47.8%) 14 (29.2%) 0.123 8 (25.0%) 6 (37.5%) 0.175
  ≤2 cm 12 (52.2%) 34 (70.8%)   24 (75.0%) 10 (62.5%)  
  >2 cm       
pLymph node status 19 (82.6%) 44 (91.7%) 0.162 30 (93.8%) 14 (87.5%) 0.460
  Negative 4 (17.4%) 4 (8.3%)   2 (6.2%) 2 (12.5%)  
  Positive       
Lymphovascular invasion 16 (69.6%) 40 (83.3%) 0.184 29 (90.6%) 11 (68.8%) 0.057
  Negative 7 (30.4%) 8 (16.7%)   3 (9.4%) 5 (32.2%)  
  Positive       
HR (ER and / or PR) 1 (4.3%) 2 (4.2%) 0.454 1 (3.1%) 1 (6.3%) 0.453
  Negative 22 (95.7%) 46 (95.8%)   31 (96.9%) 15 (93.7%)  
  Positive       
HER2 status 23 (100.0%) 47 (97.9%) 0.676 31 (96.9%) 16 (100.0%) 0.667
  Negative 0 (0.0%) 1 (2.1%)   1 (3.1%) 0 (0.0%)  
  Positive       
Ki67 17 (73.9%) 46 (95.8%) 0.010 30 (93.8%) 16 (100.0%) 0.439
  Negative 6 (26.1%) 2 (4.2%)   2 (6.2%) 0 (0.0%)  
  Positive       
Nuclear grade 11 (47.8%) 44 (91.7%) < 0.001 30 (93.8%) 14 (87.5%) 0.306
  1 12 (52.2%) 4 (8.3%)   2 (6.2%) 2 (22.5%)  
  2 and 3       
EIC 12 (52.2%) 28 (58.3%) 0.624 20 (62.5%) 8 (50.0%) 0.174
  Negative 11 (47.8%) 20 (41.7%)   12 (37.5%) 8 (50.0%)  
  Positive       
  1. BMC breast mucinous carcinoma, MMBC mixed mucinous carcinoma, PMBC pure mucinous carcinoma, HR Hormone receptor, EIC extensive intraductal component.